A detailed history of Voloridge Investment Management, LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Voloridge Investment Management, LLC holds 975,300 shares of VIR stock, worth $7.2 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
975,300
Previous 1,224,898 20.38%
Holding current value
$7.2 Million
Previous $10.9 Million 33.0%
% of portfolio
0.03%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.26 - $10.7 $1.81 Million - $2.67 Million
-249,598 Reduced 20.38%
975,300 $7.3 Million
Q2 2024

Aug 14, 2024

BUY
$7.63 - $12.66 $3.98 Million - $6.6 Million
521,370 Added 74.11%
1,224,898 $10.9 Million
Q1 2024

May 15, 2024

BUY
$8.6 - $11.9 $1.29 Million - $1.78 Million
149,722 Added 27.04%
703,528 $7.13 Million
Q4 2023

Feb 14, 2024

BUY
$7.76 - $10.29 $877,174 - $1.16 Million
113,038 Added 25.65%
553,806 $5.57 Million
Q3 2023

Nov 14, 2023

BUY
$9.14 - $24.62 $4.03 Million - $10.9 Million
440,768 New
440,768 $4.13 Million
Q1 2022

May 16, 2022

SELL
$21.19 - $40.01 $7.52 Million - $14.2 Million
-355,091 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$30.97 - $54.03 $4.76 Million - $8.3 Million
153,578 Added 76.21%
355,091 $14.9 Million
Q3 2021

Nov 15, 2021

SELL
$34.9 - $54.54 $232,294 - $363,018
-6,656 Reduced 3.2%
201,513 $8.77 Million
Q2 2021

Aug 16, 2021

SELL
$38.75 - $51.0 $2.93 Million - $3.86 Million
-75,600 Reduced 26.64%
208,169 $9.84 Million
Q1 2021

May 17, 2021

SELL
$26.34 - $83.07 $1.77 Million - $5.6 Million
-67,356 Reduced 19.18%
283,769 $14.5 Million
Q4 2020

Feb 16, 2021

BUY
$25.51 - $43.38 $8.96 Million - $15.2 Million
351,125 New
351,125 $9.4 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $979M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Voloridge Investment Management, LLC Portfolio

Follow Voloridge Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voloridge Investment Management, LLC with notifications on news.